Kalos Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Kalos Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-14,050	Closed	-$27K	–	131
2022 Q2	$27K	Sell	14,050 -500	-3%	-$1.09K	0.04%	131
2022 Q1	$43K	Buy	+14,550	New	+$54.7K	0.03%	167
2021 Q4	–	Sell	-15,550	Closed	-$77K	–	288
2021 Q3	$77K	Sell	15,550 -4,000	-20%	-$22K	0.02%	285
2021 Q2	$127K	Hold	19,550	–	–	0.05%	250
2021 Q1	$138K	Sell	19,550 -2,500	-11%	-$18K	0.04%	277
2020 Q4	$138K	Sell	22,050 -2,500	-10%	-$14.7K	0.06%	234
2020 Q3	$136K	Sell	24,550 -500	-2%	-$2.48K	0.06%	213
2020 Q2	$130K	Hold	25,050	–	–	0.05%	201
2020 Q1	$78K	Hold	25,050	–	–	0.03%	193
2019 Q4	$100K	Hold	25,050	–	–	0.04%	191
2019 Q3	$107K	Sell	25,050 -5,000	-17%	-$20K	0.04%	183
2019 Q2	$119K	Buy	30,050 +3,483	+13%	+$16.6K	0.05%	181
2019 Q1	$142K	Buy	26,567 +2,117	+9%	+$13.7K	0.09%	144
2018 Q4	$160K	Buy	24,450 +11,000	+82%	+$83.5K	0.08%	171
2018 Q3	$115K	Buy	+13,450	New	+$136K	0.06%	155

Other funds holding PRTK

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

1CM

1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return

Kalos Management's PRTK Position: Q3 2022 in Review

Kalos Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2022, closing a stake of 14,050 shares — an estimated $27K sold.

Kalos Management first reported a position in PRTK in Q3 2018 and held it in 15 quarters. The position peaked at $160K in Q4 2018. 72 funds tracked by Wall St. Rank hold PRTK as of Q3 2022.

Kalos Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
Kalos Management sold 14,050 Paratek Pharmaceuticals, Inc. shares in Q3 2022, an estimated $27K.
Kalos Management first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2018 and held it in 15 quarters.
Kalos Management's Paratek Pharmaceuticals, Inc. position peaked at $160K in Q4 2018.
72 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2022.

Based on Kalos Management's 13F filing for Q3 2022, filed 21 Nov 2022.